Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Quest Diagnostics Inc (DGX) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance

Quest Diagnostics IncTrade
Vanguard Tax Managed Fund FTSE Developed Markets ETFTrade

Price performance (Past 24H)

Key statistics

Quest Diagnostics Inc vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Quest Diagnostics Inc trades at $238.02 (market cap $26.21B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $73.25. The key difference: Quest Diagnostics Inc pays a 1.45% dividend while Vanguard Tax Managed Fund FTSE Developed Markets ETF pays none. Which is the better fit depends on your goals.

DGXVEA
Market Cap
$26.21B
Sector
Health
52-Week High
$238.50$72.89
52-Week Low
$173.49$58.19
Enterprise Value
$31.97B
Dividend Yield
1.45%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.

DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.

Vanguard Tax Managed Fund FTSE Developed Markets ETF

VEA trades at $73.31, up 1.12% with a bullish technical signal from moving averages. The ETF shows mixed institutional activity with both new acquisitions and position reductions. Recent news highlights VEA's competitive advantages in expense ratios and international diversification compared to peers like SPGM and NZAC.

Outlook remains positive given strong technical momentum and cost advantages, though overbought RSI signals near-term caution. Key risks include international market volatility and currency fluctuations. The ETF's low-cost structure and developed market exposure provide long-term diversification benefits for US investors.

Returns comparison

Trailing returns across standard periods

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX

About Vanguard Tax Managed Fund FTSE Developed Markets ETF

The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.

Read more on VEA